About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Different Doses of ZED1227 vs. Placebo in NAFLD

NCT05305599·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Dr. Falk Pharma GmbH

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Has provided signed informed consent
Is a male or female ≥ 18 and \< 75 years of age
Has diagnosed NAFLD
Has diagnosed significant fibrosis (stages 2 or 3)

You may not be if

Has a history of significant alcohol consumption (an average of \> 20 g/d in females and \> 30 g/d in males)
Has a history or presence of any other significant concomitant liver diseases
Has diagnosed type 1 diabetes mellitus (T1DM)
Has presence of cirrhosis

The record

StatusCompleted

PhasePhase 2

Taking part186

StartedApr 2022

UpdatedMay 14, 2024

Conditions

NAFLD Liver Fibrosis

Where1

Department of Medicine, University Medical Centre, Johannes Gutenberg University Mainz
Mainz, Rhineland-Palatinate, Germany

Clareo Health | Different Doses of ZED1227 vs. Placebo in NAFLD